In this episode of Voice of Stroke, we explore new evidence shaping how lipid management can reduce stroke risk across both primary and secondary prevention.
This episode explores:
Reassessing statin side effects using large-scale randomised trial data
The role of PCSK9 inhibition (VESALIUS-CV) in reducing vascular events in high-risk patients without prior stroke
Long-term data linking LDL, lipoprotein(a), and inflammation to stroke risk decades later
Together, these findings clarify safety concerns, expand preventive options, and highlight the importance of long-term risk prediction in stroke care.
This episode was written by Linxin Li, Editor-in-Chief of the Voice of Stroke Podcast, and Co-Editor Ahmad Nehme.
Note: Full transcript available here.
The following publications were mentioned in this podcast:
NEJM paper on the VESALIUS-CV trial
Lancet paper on statin side effects
Lancet Neurology paper on prediction of long-term stroke risk
2026 AHA/ACC guideline on lipid management
International Journal of Stroke review on lipid management